Table 5. Blood chemistry results, hematologic measures, and liver enzyme values for the hyperlipidemia patients.
|
Placebo (n = 50) |
Mangiferin (n = 47) |
P | |||
|---|---|---|---|---|---|
| Baseline | End of intervention | Baseline | End of intervention | ||
| Hemoglobin (g/L) | 133.8 ± 10.2 | 134.4 ± 8.1 | 135.2 ± 11.0 | 132.9 ± 11.6 | 0.455 |
| Red blood cells (×1012 /L) | 4.58 ± 0.47 | 4.57 ± 0.41 | 4.62 ± 0.38 | 4.69 ± 0.32 | 0.151 |
| White blood cells (×1012 /L) | 6.63 ± 1.48 | 6.61 ± 1.77 | 6.59 ± 1.61 | 6.62 ± 1.44 | 0.975 |
| Platelets (×109 /L) | 205.7 ± 31.5 | 203.6 ± 32.8 | 211.2 ± 35.6 | 211.3 ± 33.4 | 0.248 |
| Total protein (g/L) | 74.7 ± 4.9 | 76.1 ± 5.8 | 75.7 ± 5.5 | 74.7 ± 5.3 | 0.211 |
| Albumin (g/L) | 41.7 ± 3.6 | 42.1 ± 3.8 | 42.4 ± 3.0 | 41.7 ± 3.6 | 0.590 |
| Aspartate transaminase (U/L) | 27.7 ± 7.6 | 27.2 ± 7.8 | 25.7 ± 8.7 | 25.7 ± 6.4 | 0.296 |
| Alanine transaminase (U/L) | 14.4 ± 5.5 | 14.1 ± 5.9 | 14.4 ± 5.1 | 14.4 ± 5.6 | 0.795 |
| Urea nitrogen (mmol/L) | 5.2 ± 0.8 | 5.2 ± 0.8 | 5.2 ± 0.8 | 5.0 ± 0.7 | 0.186 |
| Creatinine (μmol/L) | 70.5 ± 9.5 | 70.6 ± 11.7 | 71.0 ± 10.7 | 71.6 ± 9.6 | 0.641 |
P values were calculated for the differences between the placebo and mangiferin groups at 12 weeks. The effects of the mangiferin intervention on these variables were analyzed by ANCOVA, with the baseline values of serum mangiferin, age, gender, BMI, blood pressure, dietary intake, hyperlipidemia duration, and drug treatment used as covariates.